Editor’s note: A recording of the event is embedded below.
After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.
advertisement
Featured Speakers
- Irena Melnikova, Ph.D., partner, Pfizer Ventures
- Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
- Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Lab trade group sues FDA to halt regulation of lab
Next article： Cancer drug shortages should be causing more outrage
Next article： Cancer drug shortages should be causing more outrage
